NCT00053742View on ClinicalTrials.gov

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

March 31, 2006

Conditions
Healthy
Interventions
DRUG

Modified Vaccinia Virus Ankara TBC-MVA

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00053742 - Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox | Biotech Hunter | Biotech Hunter